Core B: Biospecimen Repository and Processing Core

核心B摘要 靶向治疗转移性黑色素瘤的最新进展最初是非常成功的 但最终会受到肿瘤抗药性发展的限制。另一方面，检查点抑制剂是 与持久的反应有关，但只对少数患者有利。这个项目中所有项目的目标 应用的是了解机制和制定策略，以克服两者的阻力相结合 黑色素瘤的靶向治疗和检查点抑制免疫治疗。拟议的研究需要一个 高效的生物素核心，可以为研究人员提供各种高质量的生物素材。这个 PPG的生物制品储存库和处理核心(BRPC-Core B)的具体目标是：1) 集中执行专门的病理服务，包括生物样本(组织和生物液体)存储， 跟踪、分布和分析；2)提供具有良好特征的黑色素瘤组织、细胞系和短期 接受联合治疗并接受BRAF/MEK抑制剂或Checkpoint治疗的患者的培养 抑制剂，并有望开发更多的细胞系；以及3)开发更好地表征细胞的技术 从肿瘤微环境中进行更复杂的原位和单细胞水平分析。BRPC 提供黑色素瘤生物学、细胞系开发、病理解释和 所有拟议研究所要求的生物库管理。

CORE B ABSTRACT Recent advances in the treatment of metastatic melanoma with targeted therapies are highly successful initially but are ultimately limited by the development of tumor resistance. On the other hand, checkpoint inhibitors are associated with durable responses but only benefit a minority of patients. The aims of all of the projects in this application are to understand the mechanisms and develop strategies to overcome resistance to both combined targeted therapies and checkpoint inhibitor immunotherapies in melanoma. The proposed studies require an efficient Biospecimen Core that can provide a variety of high quality biospecimens to the investigators. The specific aims of the Biospecimen Repository and Processing Core (BRPC - Core B) of the PPG are to: 1 ) Centralize performance of specialized pathology services, including biosample (tissue and biofluid) storage, tracking, distribution and analysis; 2) Provide well-characterized melanoma tissues, cell lines and short-term cultures from patients enrolled on combination therapies and treated with BRAF/MEK inhibitors or checkpoint inhibitors and prospectively develop additional cell lines; and 3) Develop techniques to better characterize cells from within the tumor microenvironment for more sophisticated analysis in situ and at the single cell level. BRPC provide the advanced expertise in melanoma biology, cell line development, pathologic interpretation and biorepository management that is required by all proposed studies.